BACKGROUND: Myeloablative allogeneic hematopoietic stem-cell transplantation is curative in children with sickle cell disease, but in adults the procedure is unduly toxic. Graft rejection and graft-versus-host disease (GVHD) are additional barriers to its success. We performed nonmyeloablative stem-cell transplantation in adults with sickle cell disease. METHODS: Ten adults (age range, 16 to 45 years) with severe sickle cell disease underwent nonmyeloablative transplantation with CD34+ peripheral-blood stem cells, mobilized by granulocyte colony-stimulating factor (G-CSF), which were obtained from HLA-matched siblings. The patients received 300 cGy of total-body irradiation plus alemtuzumab before transplantation, and sirolimus was administered afterward. RESULTS: All 10 patients were alive at a median follow-up of 30 months after transplantation (range, 15 to 54). Nine patients had long-term, stable donor lymphohematopoietic engraftment at levels that sufficed to reverse the sickle cell disease phenotype. Mean (+/-SE) donor-recipient chimerism for T cells (CD3+) and myeloid cells (CD14+15+) was 53.3+/-8.6% and 83.3+/-10.3%, respectively, in the nine patients whose grafts were successful. Hemoglobin values before transplantation and at the last follow-up assessment were 9.0+/-0.3 and 12.6+/-0.5 g per deciliter, respectively. Serious adverse events included the narcotic-withdrawal syndrome and sirolimus-associated pneumonitis and arthralgia. Neither acute nor chronic GVHD developed in any patient. CONCLUSIONS: A protocol for nonmyeloablative allogeneic hematopoietic stem-cell transplantation that includes total-body irradiation and treatment with alemtuzumab and sirolimus can achieve stable, mixed donor-recipient chimerism and reverse the sickle cell phenotype. (ClinicalTrials.gov number, NCT00061568.) 2009 Massachusetts Medical Society
BACKGROUND: Myeloablative allogeneic hematopoietic stem-cell transplantation is curative in children with sickle cell disease, but in adults the procedure is unduly toxic. Graft rejection and graft-versus-host disease (GVHD) are additional barriers to its success. We performed nonmyeloablative stem-cell transplantation in adults with sickle cell disease. METHODS: Ten adults (age range, 16 to 45 years) with severe sickle cell disease underwent nonmyeloablative transplantation with CD34+ peripheral-blood stem cells, mobilized by granulocyte colony-stimulating factor (G-CSF), which were obtained from HLA-matched siblings. The patients received 300 cGy of total-body irradiation plus alemtuzumab before transplantation, and sirolimus was administered afterward. RESULTS: All 10 patients were alive at a median follow-up of 30 months after transplantation (range, 15 to 54). Nine patients had long-term, stable donor lymphohematopoietic engraftment at levels that sufficed to reverse the sickle cell disease phenotype. Mean (+/-SE) donor-recipient chimerism for T cells (CD3+) and myeloid cells (CD14+15+) was 53.3+/-8.6% and 83.3+/-10.3%, respectively, in the nine patients whose grafts were successful. Hemoglobin values before transplantation and at the last follow-up assessment were 9.0+/-0.3 and 12.6+/-0.5 g per deciliter, respectively. Serious adverse events included the narcotic-withdrawal syndrome and sirolimus-associated pneumonitis and arthralgia. Neither acute nor chronic GVHD developed in any patient. CONCLUSIONS: A protocol for nonmyeloablative allogeneic hematopoietic stem-cell transplantation that includes total-body irradiation and treatment with alemtuzumab and sirolimus can achieve stable, mixed donor-recipient chimerism and reverse the sickle cell phenotype. (ClinicalTrials.gov number, NCT00061568.) 2009 Massachusetts Medical Society
Authors: Christopher J Fraser; Smita Bhatia; Kirsten Ness; Andrea Carter; Liton Francisco; Mukta Arora; Pablo Parker; Stephen Forman; Daniel Weisdorf; James G Gurney; K Scott Baker Journal: Blood Date: 2006-06-20 Impact factor: 22.113
Authors: Jonathan D Powell; Courtney Fitzhugh; Elizabeth M Kang; Mathew Hsieh; Ronald H Schwartz; John F Tisdale Journal: Transplantation Date: 2005-12-15 Impact factor: 4.939
Authors: L M Griffith; J P McCoy; C D Bolan; D F Stroncek; A C Pickett; G F Linton; A Lundqvist; R Srinivasan; S F Leitman; R W Childs Journal: Br J Haematol Date: 2005-03 Impact factor: 6.998
Authors: Ramaprasad Srinivasan; Yoshiyuki Takahashi; J Philip McCoy; Igor Espinoza-Delgado; Colleen Dorrance; Takehito Igarashi; Andreas Lundqvist; A John Barrett; Neal S Young; Nancy Geller; Richard W Childs Journal: Br J Haematol Date: 2006-05 Impact factor: 6.998
Authors: Anastasia Anthi; Roberto F Machado; Maria L Jison; Angelo M Taveira-Dasilva; Lewis J Rubin; Lori Hunter; Christian J Hunter; Wynona Coles; James Nichols; Nilo A Avila; Vandana Sachdev; Clara C Chen; Mark T Gladwin Journal: Am J Respir Crit Care Med Date: 2007-03-22 Impact factor: 21.405
Authors: Corey Cutler; Shuli Li; Vincent T Ho; John Koreth; Edwin Alyea; Robert J Soiffer; Joseph H Antin Journal: Blood Date: 2007-04-01 Impact factor: 22.113
Authors: J J A Coenen; H J P M Koenen; E van Rijssen; A Kasran; L Boon; L B Hilbrands; I Joosten Journal: Bone Marrow Transplant Date: 2007-03-12 Impact factor: 5.483
Authors: Helen Gharwan; Nicola M Neary; Mary Link; Matthew M Hsieh; Courtney D Fitzhugh; Richard J Sherins; John F Tisdale Journal: Endocr Pract Date: 2014-09 Impact factor: 3.443